FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma By Ogkologos - July 18, 2025 837 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Breast Cancer Survivor Comes First Woman In The World To Give... June 17, 2020 News digest – naked mole-rats, junk food deals, ovarian cancer drug... July 4, 2020 Mom Wants Disney To Ban Childless Adults From Their Theme Parks July 29, 2019 Uncle Charlie’s Promise February 23, 2021 Load more HOT NEWS Trial Examines Value of Lymph Node Surgery in Advanced Ovarian Cancer The digital shift: How are remote GP appointments affecting cancer patients? Inavolisib Plus Palbociclib–Fulvestrant Prolongs PFS in Patients with PIK3CA-mutated, HR-positive, HER2-negative... New Study Shows Intermittent Fasting May Reduce Breast Cancer Risk and...
